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1.0 	SUBSTANCE USE DISORDER: A global health problem
	Drug and alcohol addiction is a chronic relapsing disorder that negatively affects the health of the individual, threatens public health, and burdens families, communities, and countries both socially and economically (Wang, Kapoor, & Goate, 2012).  In 2010, the United Nations Office on Drugs and Crime (UNODC) World Drug Report (2013) estimated that 27 million adults, 0.6% of the world’s adult population, suffered from addiction.  Addiction is a psychological and behavioral disorder that manifests itself in: the compulsion to take a substance, fixation on taking the substance, and an inability to limit the intake of the substance (Koob & Le Moal, 2001).  Individuals suffering from addiction often have repeated attempts to reduce or stop drug use without success, and continue to use drugs despite experiencing significant negative consequences (Olive et al., 2012).  The term addict has many negative connotations associated with it, as addiction was historically viewed as a failure of morality rather than a psychological disorder.  Due to the severity of the negative stigma associated with the terms addiction and addict, the terms substance use disorder and substance abuser/substance dependent are being used instead (American Psychiatric Association, 2013).   Substance use disorders can occur with illicit substances as well as legal substances, such as alcohol, nicotine, and caffeine.  Illicit drugs refer to any substance whose “non-medical use has been prohibited under international drug control treaties” (Degenhardt et al., 2013).  Illicit substances can include: heroin, cocaine, cannabis, amphetamines, methylenedioxy-methamfetamine (MDMA), and pharmaceutical drugs like buprenorphine, methadone, opioids, and benzodiazepines that are taken without a valid medical prescription (Degenhardt & Hall, 2012).  Most countries divide illicit drugs into four drug classes: opioids, amphetamines, cocaine, and cannabis.  
1.1	global trafficking patterns of illicit drugs
In 2010, roughly 230 million adults, 5% of the world’s adult population, used an illicit drug at least once (United Nations Office on Drugs and Crime, 2013).  The World Drug Report 2010 (2013) estimated that heroin, cocaine and other drugs kill roughly 200,000 people each year, destroying families and individuals alike.  As illicit drug use occurs across the globe, the trafficking and use of illicit substances is a global problem (United Nations Office on Drugs and Crime, 2015).  Drugs are cultivated and manufactured in specific regions of the world; due to both legal and illegal trade, access to any specific substance has expanded with the drug market.  As Figure 1 (below) shows, opiates are cultivated and manufactured in only a few locations, but the flow via trade routes traverse the globe.  Other illicit drugs of abuse, such as cannabis and cocaine, demonstrate similar flow patterns based on their origin. 


Source: United Nations Office on Drugs and Crime, World Drug Report 2015
Figure 1. The Global Reach of Regional Drug Production: Opiates


For opiates, Mexico and Columbia produce the majority of the illicit supply used in the Western Hemisphere, while Afghanistan and Myanmar produce most of the opiates for Europe, Africa, Asia and Australia.  To better understand the impact of substance use and abuse, an analysis of the global use of various substances is necessary before discussing the burdens chronic use puts on the individual, their families, and society at large.  
1.2	SUBSTANCE USE: the scope of the problem
The United Nations Office on Drugs and Crime (UNODC) monitors drug consumption and use through annual report questionnaires and individual drug seizure databases, releasing a report periodically on its findings (United Nations Office on Drugs and Crime, 2015).  In the 2009 report, the UNODC estimated that 149-271 (mean 210) million individuals between the ages of 15 and 64 had used an illicit drug at least once in the past year (United Nations Office on Drugs and Crime, 2009).  In the 2015 report, the UNODC estimated that 160-325 (mean 246) million individuals used an illicit drug in 2013, indicating an increase in the incidence of illicit drug use from 2009 to 2013 of 36 million when comparing average estimates (United Nations Office on Drugs and Crime, 2015; United Nations Office on Drugs and Crime, 2009).  Among substance users, it is estimated that roughly 10% of the population is physically addicted at any given time (United Nations Office on Drugs and Crime, 2013).  The World Drug Report findings from 2009 to 2013 show an increased incidence of substance use; this suggests that there has also been an increase in the individuals abusing drugs as well.  Although the proportion of substance abusers has remained stable at 10% of the substance user population, the number of dependent individuals is causing more strain on health systems and economies, as substance abusers experience poorer health compared to the general population, and are often unable to maintain stable employment (National Drug Intelligence Center, 2011).  
While individuals can use opioids with a valid medical prescription, the UNODC only monitors illicit uses of opioids (United Nations Office on Drugs and Crime, 2013).  The global prevalence of opioid use is estimated to be 0.7% of the world’s adult population, or 32.4 million users; for North America though, the prevalence of illegal opioid use is much higher, at 3.8% of the adult population (United Nations Office on Drugs and Crime, 2015).  Abuse of prescription opioids is most likely the cause of this high prevalence, based on the actions taken by the FDA, and the increase in drug-poisoning deaths caused by opioids in the US (Figure 2, below).  In an attempt to curb opioid abuse in the US, the FDA approved a formulation change of extended-release oxycodone in 2010 (Butler et al., 2013).  The change in formula made it more difficult for extended-release oxycodone to be abused, as abusers typically crushed it into a powder for snorting, or dissolved it in a liquid for injecting in order to bypass the extended-release format to achieve a stronger high (Cicero, Ellis & Surratt, 2012).  While opioid abuse for extended-release oxycodone plateaued after 2012 (Figure 2), an unforeseen consequence was that heroin use in the US rose drastically, as it was easier to acquire and cheaper than the reformulated extended-release oxycodone for individuals who intended to abuse opioids (Cicero, Ellis & Surratt, 2012).  As heroin use increased, the number of deaths from heroin overdose exploded, from 3,036 in 2010 to 8,257 in 2013, an increase of 272% (United Nations Office on Drugs and Crime, 2015; Hedegaard, Chen & Warner, 2015).  


Source: Hedegaard, Chen & Warner, 2015.
Figure 2. Drug-Poisoning Deaths Involving Heroin and Opioids: US Statistics
The use and abuse rate for other substances varies.  Alcohol is one of the few legal substances of abuse that adults consume globally.  The World Health Organization Global Status Report on Alcohol and the World Health Organization Global Information System on Alcohol and Health provide regular updates regarding exposure data for alcohol consumption in adults, using government records and industry publications on production and sales of alcohol, as well as data provided by the Food and Agriculture Organization (Rehm et al., 2009).  In Figure 3 (below), a colorized map shows estimates on the total consumption of alcohol in liters per adult per year by country, demonstrating the significant variance in consumption patterns globally.  


Source: Rehm et al., 2009. 
Figure 3. Global Alcohol Consumption Patterns

The following statistics are based on the UNODC World Drug Report 2015.  Based on annual report questionnaires, cocaine use has declined globally since 2009, with 0.4% of the global population aged 15-64 (roughly 20 million people) using the substance in 2013, while cannabis use continues to increase, with an estimated 4.9% of the global population aged 15-64 (roughly 180 million people) using cannabis in 2013.  Amphetamine-like drug use has also risen as the market expands in South-East Asia, with an estimated 1.1% of the global population aged 15-64 (roughly 53 million individuals) using amphetamines in 2013; crystal methamphetamine use has increased in North America and Europe in particular.  Prevalence rates for psychoactive substances are difficult to estimate due to their transient and diverse use (United Nations Office on Drugs and Crime, 2015).  While prevalence is difficult to measure, the number of new psychoactive substances (NPS) can be counted through surveillance with law enforcement laboratories.  Also referred to as “legal highs” and “bath salts,” NPS are substances that are not controlled by the 1961 Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances but pose a public health threat (United Nations Office on Drugs and Crime, 2016).  The term “new substance” refers to any substance that was not seen in the previous year, as opposed to a substance newly created.  It is also important to note that countries report new substances differently, as some do not distinguish between chemically similar substances, while others do.  The UNODC monitors NPS because their use is frequently linked to health problems; side effects from NPS use can include: seizures, agitation, aggression, acute psychosis and death (United Nations Office on Drugs and Crime, 2016).  As shown in Figure 4 (below), since 2009 there has been a steady increase in the new psychoactive substances used by individuals.

Sources: United Nations Office on Drugs and Crime, 2015; 
United Nations Office on Drugs and Crime, 2016.

Figure 4. Number of New Psychoactive Substances Reported

In 2009, 126 new psychoactive substances were reported; since then, the number has continued to rise, more than tripling by 2013 with 430 new substances reported, and reaching 450 substances in 2014 (United Nations Office on Drugs and Crime, 2015).  The UNODC Early Warning Advisory on NPS (2016) reported 643 new psychoactive substances, with 75 reported for the first time in 2015; the emergence of NPS has spread to over 100 countries. 
2.0 	Substance Use Disorder: A clinical picture
Physicians, social workers, public health workers, insurance companies, the criminal justice system and other organizations rely on two main sources for describing substance use disorders: the International Classification of Diseases 10th Revision (ICD-10), and the Diagnostic and Statistical Manual for Mental Disorders 5th Edition (DSM-V).  The ICD-10 defines a person as being drug dependent when they have exhibited at least 3 of the following indicators of dependence within the past year (World Health Organization, 1992): 
(a) A strong desire/compulsion to take the substance; 
(b) Difficulty in controlling substance use, such as: onset, termination, or quantity; 
(c) Withdrawal symptoms based on the type of drug used, including the use of the same/similar substance to relieve/circumvent withdrawal symptoms; 
(d) Tolerance, such that increased doses are required to achieve the same effect;
(e) Neglect of previously enjoyed activities, with more time spent trying to obtain or take the substance; 
(f) Continued substance use despite harmful effects.
The DSM-V goes further by classifying the severity of the illness based on the number of symptoms experienced by the individual: 2-3 symptoms indicate mild disorder, 4-5 indicate moderate disorder, and 6 or more indicate severe disorder (American Psychiatric Association, 2013).  These eleven symptoms, or criteria, are divided into four groups, below:  
Impaired Control (Criterion 1-4):
1) Taking the substance in larger quantities or for a longer period of time than was initially intended;
2) A desire to decrease or control substance use, with any attempt to do so being generally unsuccessful;
3) More time spent getting the substance, using the substance, or recovering from the substance;
4) Craving;
Social Impairment (Criterion 5-7):
5) Failure to fulfill work, school, or home obligations;
6) Continued substance use despite experiencing social or interpersonal problems caused or made worse by the effects of the substance;
7) Reduction or elimination of social, occupational, or recreational activities because of substance use;
Risky Use (Criterion 8-9):
8) Substance use in situations where it becomes physically hazardous to do so;	
9) Continued use despite knowledge of a physical or psychological problem caused by or made worse by the taking of the substance;




The mechanisms of drug dependence are difficult to study in humans due to ethical concerns over causing undue harm to research patients (Demers, Bogdan & Agrawal, 2014).  However, through the use of imaging studies of addicted individuals and the utility of animal models like rodents and drosophila, certain aspects of drug dependence have been elucidated.  Drugs of dependence act directly upon the brain’s reward system, altering brain chemistry so that behaviors involving drug use are reinforced while ordinary behaviors might be neglected (American Psychiatric Association, 2013).  In a mouse model designed for studying the mechanisms of substance abuse, female mice were allowed to self-administer cocaine by pressing a lever; this behavior was so strongly reinforced for acquiring cocaine that the mice neglected their basic needs such as food and water, overdosing on cocaine (Griffin & Middaugh, 2003).  
Both positive and negative reinforcement occurs with drug abuse (Koob & Le Moal, 2001).  Positive reinforcement occurs with initial drug use as the user experiences a sense of pleasure without detriment.  These drugs react with various receptors in the brain, increasing dopamine levels in the nucleus accumbens, a central node in the reward circuit (Volkow & Muenke, 2012), as demonstrated through imaging studies in humans (Van den Oever, Spijker & Smit, 2012).  This flood of dopamine causes the sense of euphoria experienced by many illicit drugs (Volkow & Muenke, 2012).  As drug use continues recreationally, this abnormal release of dopamine becomes more difficult to attain, as neuroplasticity weakens with continued drug use, meaning that the brain is unable to recover to the pre-drug baseline of chemical response (Van den Oever, Spijker & Smit, 2012).  The loss of neuroplasticity leads to tolerance of the drug, as greater quantities of the substance are required to create the same neurotransmitter response and dopamine release (Volkow & Muenke, 2012).  At some point during substance use, an allostatic change occurs, where this deviation of the reward system becomes chronically altered.  In addition to causing deviations in the reward system, drugs of abuse act upon other neurochemicals and the stress response system, causing pathophysiologic changes that may also be permanent, observed through imaging studies in humans and rodent models (Van den Oever, Spijker & Smit, 2012).  In humans, brain imaging studies on former addicts have been performed demonstrating that pictures of drug use can stimulate the same areas of the brain as are active during actual drug use; despite long periods of abstinence, these former substance abusers exhibit the same neuronal response as they did when actively using, indicating that these responses are insidious (Volkow & Muenke, 2012).  Negative reinforcement occurs as the individual continues to take the substance to avoid unwanted symptoms such as withdrawal, which is experienced as levels of the substance decrease in the blood or tissue (Koob & Le Moal, 2001).  This negative reinforcement of substance abuse has been demonstrated in rodents, drosophila, zebrafish, and through human imaging studies (Van den Oever, Spijker & Smit, 2012).  
Withdrawal from drugs and alcohol can vary by symptoms, intensity and length considerably.  For alcohol use disorder, withdrawal symptoms usually develop 4-12 hours after the conclusion of heavy alcohol consumption (Schuckit, 2012).  Alcohol withdrawal can be life threatening, and clinical diagnosis requires at least two of the following symptoms: insomnia, autonomic dysfunction (i.e. increased heart rate, sweating), tremors, nausea, vomiting, restlessness, anxiety, seizures, and/or hallucinations (Manasco et al., 2012).  Some symptoms may persist for months afterwards, such as sleeping problems and mood changes, often contributing to relapse.    Heavy and prolonged alcohol consumption can damage the gastrointestinal tract, cardiovascular system, the peripheral and central nervous systems, and most organs (Goodman et al., 2011).  Gastritis, stomach and intestinal ulcers, liver cirrhosis, pancreatitis, cancer, cardiomyopathy, heart disease, muscle weakness, cognitive deficits, memory impairment, and an increased risk for suicide are all potential complications directly caused by continued excessive alcohol consumption (Rehm et al., 2009).  These complications are more frequently observed in men over 35, as they have a higher prevalence of alcohol abuse compared to women; more specifically, these complications are more frequently observed in Caucasian men and Latino men, as they have higher rates of alcohol abuse compared to African American men (Cook & Alegria, 2011).  Separately, pregnant women with active alcohol use disorder increase the risk for birth defects, low birth weight, pre-term delivery, and fetal alcohol syndrome for their fetus (Rehm et al., 2009).  
Withdrawal symptoms from other substances of abuse are similar to those of alcohol, but can differ in clinical diagnostics and length.  Cannabis withdrawal symptoms can include: irritability, anger/aggression, anxiety, depression, restlessness, sleep disturbances, and changes to appetite (Budney et al., 2004; Levin et al., 2010).  A diagnosis of withdrawal from opioids requires at least three of the following symptoms: dysmorphic mood, diarrhea, nausea, vomiting, abdominal cramps, dilation of pupils, sweating, fever, insomnia, high blood pressure, heart palpitations, and extreme discomfort (Ries et al., 2014).  Symptoms for opiate withdrawal can begin within 24 hours of cessation, and can last for up to 14 days with heroin.  As with alcohol withdrawal, some symptoms may linger for extended periods of time, such as dysmorphic mood and sleep problems, however opioid withdrawal is generally not life threatening.  Conversely, cocaine withdrawal can be fatal, with the individual at risk for stroke, seizures, respiratory failure, myocardial infarctions, and hallucinations (Hazelden Betty Ford Foundation, 2016).  Amphetamine and methamphetamine withdrawal can include aggressive or violent behavior, dysphoric mood symptoms such as: intense anxiety, psychotic episodes and depression, hypersomnia, and increased appetite and cravings (American Psychiatric Association, 2013).
2.2	BURDEN OF DISEASE
Almost 5% of the global burden of disease and injury was due to alcohol in 2004 (Rehm et al., 2009).  Substance abusers are at greater risk for and have higher rates of many infectious diseases, with roughly 30% of drug injectors living with HIV (Chandler, Fletcher & Volkow, 2009).  Among those, many may not be receiving antiretroviral therapy-particularly if they are unaware of their HIV-status, and may not have access to needle replacement facilities to prevent the spread of blood-borne diseases to others (Degenhardt et al., 2013).  Tuberculosis, Hepatitis C and Hepatitis B are also more prevalent in people who inject drugs, placing them at greater risk for significant morbidity and mortality (National Drug Intelligence Center, 2011).  By analyzing the Global Burden of Diseases, Injuries, and Risk Factors Study 2010, Degenhardt and colleagues (2013) found that individuals who inject drugs are more likely to become infected with Hepatitis C compared to individuals who do not inject drugs, with 52% of drug injectors currently carrying Hepatitis C globally.  In the United States, this risk of Hepatitis C infection is even higher, as greater than 70% of the drug-injecting population-more than 1.5 million Americans-is infected with Hepatitis C (Nelson et al., 2011).  
Overdose from opioids is the most common cause of drug-related deaths, with the United States observing more than 4 times the global average of drug-related mortality rates (United Nations Office on Drugs and Crime, 2015).  Since 2009, drug overdose deaths continue to outnumber motor vehicle deaths in the US each year; in 2010, 16,651 deaths were caused by opioid analgesic overdose in the US (Behavioral Health Coordinating Committee, 2013).  In 2013, the United States accounted for roughly 20% of drug-related deaths globally for the year (United Nations Office on Drugs and Crime, 2015); 47,055 drug overdose deaths occurred in the US in 2014 alone (Rudd et al., 2016).  
Individuals abusing drugs are also at an increased risk for non-fatal overdoses, which are much harder to measure.  Cross-sectional surveys of opioid users have estimated that between 30 and 80 percent have experienced an overdose, with a median of 3 nonfatal overdoses over the course of their drug history at the time of the survey, and close to half experiencing a drug overdose within the past year (United Nations Office on Drugs and Crime, 2015).  Non-fatal overdoses increase the likelihood for a fatal overdose at a later point in time, but also contribute to the burden of disease, as observed through hospitalization and treatment in acute care settings (Powis et al., 1999).  Individuals who experience a non-fatal overdose may experience complications such as pulmonary oedema, bronchopneumonia, peripheral neuropathy, renal failure, cognitive impairment, and traumatic injuries (United Nations Office on Drugs and Crime, 2015; Rehm et al., 2009).  
While low to moderate consumption of alcohol (one to two servings per day, without overconsumption) has been associated with improved cardiovascular health in both middle-aged men and women (Szmitko & Verma, 2005), overconsumption and alcohol use disorder are associated with increased risks for multiple diseases, including: oesophageal cancer, colon/rectal cancer, liver cancer, breast cancer, other neoplasms, diabetes mellitus, depression, epilepsy, hypertension, heart disease, stroke, pancreatitis, cirrhosis of the liver, fetal alcohol syndrome in infants, low birthweight, pre-term delivery, and disorders associated with perinatal development (Rehm et al., 2009).  Excessive alcohol use is the third leading cause of preventable death in the US (Lin et al., 2012).  Alcohol use disorder can cause damage to almost every organ system, damage the peripheral and central nervous system, cause paranoia, skin irritation, respiratory failure, and heart attacks (Hazelden Betty Ford Foundation, 2016).  
Long-term cannabis use has been linked to fertility complications, immune system damage, and memory problems (Oyemade, 2008).  Methamphetamines can cause permanent tooth loss, violent mood swings, brain damage (Hazelden Betty Ford Foundation, 2016), and inhibit the innate immune system (Oyemade, 2008).  Inhibition of the innate immune system by methamphetamine has been demonstrated by increased replication of HCV in human hepatocytes, and a decreased response to recombinant interferon alpha treatment (Ye et al., 2008).  These symptoms can often affect the individual long after substance use has stopped.  In 2010, substance use disorders accounted for 7.4% of the disability-adjusted life years (DALYs), and 22.9% of years lived with disability (YLDs) worldwide (Lynskey & Strang, 2013).  The highest rate of burden occurred in the US, UK, Russia, and Australia (Degenhardt et al., 2013).  Within the US, the burden for DALYs and YLDs was highest among men aged 20-29.
2.2.1	Comorbid Disease
Comorbid disease is prevalent among substance abusers, although research has yet to clarify if one disease causes the other, or if they co-occur due to similar genetic vulnerabilities. Attention deficit hyperactivity disorder (ADHD) has been associated with a higher risk for substance use disorder, which may be due to similar problems with disinhibition and behavioral control (Volkow & Muenke, 2012). Nicotine addiction is frequently observed as a comorbid disease for schizophrenia and depression, as well as other psychiatric illnesses (Li & Burmeister, 2009).  Roughly half of the individuals with substance use disorders also have comorbid mental illness; these individuals with comorbid mental illnesses are additionally at higher risk of becoming HIV infected (Kuehn, 2008).  An estimated 10-40% of patients in HIV clinics have the triple diagnosis of HIV, mental illness, and substance use disorder.  While this complicates treatment, as all comorbid diseases need to be treated, psychiatric illness should not be a barrier to substance use treatment.
2.2.2	Changes in Care
Substance use disorder also affects pain management in acute care.  Due to tolerance, individuals who abuse opioids require more medication than non-abusers to alleviate pain (Dunn & Neuman, 2012).  Additionally, recovered opioid abusers are at risk for relapse if given opiates during acute care treatment, particularly if they are unable to request alternative pain medication.  Fear of over-medicating can lead to unnecessary suffering, through longer hospital stays, readmissions, increased emergency department visits, and diminished quality of life (Morgan & White, 2009).  According to a consensus statement released by the American Pain Society and the American Academy of Pain Medicine (2009), pain is often undertreated, in part because healthcare providers fear regulatory oversight by government agencies.  Individuals with chronic pain may choose to seek illicit drugs to control their pain when unable to acquire adequate pain medication from their doctor (Morgan & White, 2009).  
2.3	BURDEN ON SOCIETY
In 2007, the cost of illicit drug use surpassed $193 billion per year in the United States (National Drug Intelligence Center, 2011).  Illicit drug use impacts the economy through both direct and indirect costs to society, illustrated through three principle areas: health, crime, and productivity.  An estimated $61 billion is spent on drug related crime, $11 billion on health related costs, and $120 billion from losses in productivity.  Crime-related costs include those accrued by the criminal justice system and crime victim costs, while health costs include treatment, hospitalizations and insurance administration, and productivity costs include premature mortality and costs associated with loss of labor participation.  
Regarding crime-related costs, approximately 7.1 million adults were under criminal justice supervision in the United States in 2009, of which an estimated half met the criteria for substance use disorder (Chandler, Fletcher, & Volkow, 2009).  Some substance users resort to crime to pay for their addiction, increasing the likelihood of arrest and incarceration; the National Survey on Drug Use and Health (NDSUH) found incarceration-related TPV losses totaled $44,048,432 in men, and $4,073,517 in women due to drug use (National Drug Intelligence Center, 2011).  Areas where illicit drugs are bought and sold frequently experience increased rates of crime and property damage, which negatively affect the local community; theft on average totaled $124.57 per incident for violent crimes, and $801.66 per incident for property crimes according to the NDIC (2011).  
Chronic drug and alcohol abuse cause significant disability as demonstrated through DALYs and YLDs (Lynskey & Strang, 2013).  Through disability, drug abuse reduces employment, leaving many drug abusers unemployed, forcing them to rely on public welfare or government programs for assistance (Zuvekas, Cooper & Buchmueller, 2005).  The Substance Abuse and Mental Health Service Administration (SAMHSA) uses the NSDUH each year to obtain comprehensive information on illicit drug use in the US.  Results from this large household survey indicate that for individuals over the age of 15, there is a 17% reduction in productivity in men and an 18% reduction in productivity in women attributable to drug abuse (National Drug Intelligence Center, 2011).  Total Productivity Value (TPV) losses related to labor participation was estimated at $34,998,122 for men and $14,239,655 for women in 2007 (National Drug Intelligence Center, 2011).  Men experience greater losses in labor participation productivity due to their higher frequency of drug abuse when compared to women.  
Drug-induced premature mortality TPV losses totaled $11,710,119 in 2007 for men and $4,294,889 for women (National Drug Intelligence Center, 2011).  As substance abuse increases the risk for various diseases and can exacerbate latent psychiatric disorders, substance use disorders burden the health care system (Whiteford et al., 2013).  In addition to higher disease risk and comorbid conditions, drug use can also affect an individual’s access to life-saving organ transplants, even when the person no longer uses.  Sandhu and colleagues (2011) analyzed renal transplant data and determined that substance abusers experienced accelerated graft loss and mortality; they calculated that if substance abusers received transplants at the same rate as non-abusers, there would be a loss of 3.4 kidneys for every 1000 transplanted.  Chronic substance abusers, including former users, are more likely to have transplant failures, due to the changes wrought on their immune system by many illicit substances.  Transplant guidelines in the US request that individuals with a history of substance abuse demonstrate at least 6 months of supervised abstinence before they be placed on transplant lists (Ramos et al., 1995).  
In the United States alone, multiple government agencies are involved in eliminating illicit drugs from society.  The Department of Defense, Department of State, United States Coast Guard, Department of Homeland Security, Substance Abuse and Mental Health Services Administration, as well as many other federal, state, and local organizations designate taxpayer dollars to prevent illicit substance use (National Drug Intelligence Center, 2011).  These agencies have also instituted environmental barriers to prevent substance use and abuse, such as establishing minimum purchase laws, increasing alcohol taxes, raising the minimum drinking age to 21, and holding businesses accountable for damage inflicted on others by intoxicated and underage patrons (Institute of Medicine, 2013).  
2.4	DISPARITIES
Significant disparities exist among subpopulations of the US regarding substance abuse and access to treatment.  Individuals actively serving in the armed forces and veterans have a significantly higher burden of disease for substance use disorders compared to civilians (Institute of Medicine, 2013).  Since 2001, the voluntary military forces of the United States have encountered periods of deployment and redeployment in dangerous environments due to two separate wars.  These types of deployments result in high levels of posttraumatic stress disorder (PTSD), traumatic brain injury, substance abuse, and suicide (Blume et al., 2010; Bray et al., 2010, Marshall et al., 2012).  Based on the population-based Health Behavior Survey conducted among active members of the military (sample size 28,546) by the Department of Defense, prescription drug misuse has seen significant rises, from 1.8% in 2002 to 11.1% in 2008 (Bray et al., 2010).  Bray and colleagues also found that this same survey indicated a greater need for PTSD evaluation, as percentages rose from 6.7% in 2005 to 10.7% in 2008.  Military members also reported higher rates of suicide attempts within the past year, increasing from 0.8% in 2005 to 2.2% in 2008 (Bray et al., 2010).  Multiple deployments increase the risk for combat-related injuries as well as increased the risk for chronic conditions such as arthritis due to carrying heavy equipment for extended deployment (Institute of Medicine, 2013).  Zoroya (2010) reported that military physicians wrote 3.8 million prescriptions for pain medication in 2009, more than four times the number they wrote in 2001.  In an environment where mental illness is still greatly stigmatized, using alcohol as a coping mechanism for traumatic/stressful events and self-medication for mental illness is deemed socially acceptable by many male military members (Bray et al., 2010).  Illicit drug use has also historically been used to deal with combat fatigue, reduce pain, and cope with panic while in battle (Institute of Medicine, 2013).  Heroin and opium were widely used by military members during the war in Vietnam, with an estimated 43% of those who served using these substances at least once, and around 22% deemed dependent at some time (Robins, 1974).  Based on the 2008 Health Behavior Survey by the Department of Defense, heavy drinking had reached a prevalence of 20% among active service members, a prevalence that is significantly higher than the 5.4% observed among civilians (Schoeborn, Adams & Peregoy, 2013).  This high incidence of heavy alcohol consumption increases the risk of morbidity and mortality, causing a disparate situation for members of the military.  
Incarcerated individuals and ex-offenders experience several disparities related to substance use disorder, including higher frequencies of drug abuse and lower frequencies of treatment.  Based on the US Department of Justice Bureau of Justice Statistics (BJS) 1991 prison inmate survey and 1989 jail inmate survey, 80% of state prisoners and 70% of federal prisoners have used illicit drugs at some point in their life (Belenko, 1998).  Half of all prisoners reported using drugs or alcohol at the time they committed their offense (Cook & Alegria, 2011).  Between 1996 and 2006, the US population rose by 12%, while the US prison population rose by 33% to 2.3 million incarcerated individuals; the number of incarcerated individuals with substance use rose by 43%, to 1.9 million (Center on Addiction and Substance Abuse, 2010).  The Center on Addiction and Substance Abuse (2010) found that 1.5 million of these prisoners met DSM criteria for substance abuse.  Since only 16.6% of facilities offer professional treatment, more than 80% of inmates who could benefit from substance abuse treatment do not receive it, due to a lack of diagnosis and an inability to access sufficient treatment (Karberg & James, 2005).   
Besides being seven times more likely to have a substance use disorder than individuals in the general population, prison inmates have higher prevalence of comorbid diseases, including mental illness (32.9% of the prison population), Hepatitis B, Hepatitis C, Tuberculosis, and HIV (National Drug Intelligence Center, 2011).  Female inmates, making up 8.4% of the total inmate population in 2010, were slightly more likely to have substance use disorders compared to men (66.1% vs. 64.3%), but significantly more likely to have mental health disorders (40.5% vs 22.9%) (Center on Addiction and Substance Abuse, 2010).  Incarcerated women were also seven times more likely to have been sexually abused and four times more likely to have been physically abused before incarceration compared to incarcerated men (Center on Addiction and Substance Abuse, 2010).  
Prison inmates are more likely to be racial minorities and from low socioeconomic status, causing a greater divide from the general population.  While African Americans made up 12.3% of the US population in 2010, they made up 41% of the prison population, of which 60.2% have substance use disorders; similarly, Hispanics made up 14.8% of the US population, but 18.8% of the prison population, of which 58.3% have substance use disorders (Center on Addiction and Substance Abuse, 2010).  Caucasians made up 66.4% of the US population, but only 34.6% of the prison population, of which 73.1% have substance use disorders (Center on Addiction and Substance Abuse, 2010).  Incarcerated substance abusers are at high risk for relapse due to a number of stressors, including the stresses involved in exiting the criminal justice system, obtaining housing and employment, reuniting with family, stigmas associated with being an ex-offender, and the myriad requirements for parole (Chandler, Fletcher & Volkow, 2009).  Additionally, there can be considerable discord in the continuity of care, as individuals move from treatment in prison to treatment and follow-up care upon release (Center on Addiction and Substance Abuse, 2010).  
According to the World Drug Report, only 1 out of every 6 substance abuser has access to treatment (United Nations Office on Drugs and Crime, 2015).  A concerning statistic by itself, it becomes an even greater issue when looking at the gender gap in treatment: while 1 out of every 3 substance abuser is female, only 1 out of 5 in treatment is female, indicating that there is a disparity for women in drug treatment.  Because women are more likely to be childcare providers than are men, part of this disparity may be caused by an inability to find suitable care for dependents (Substance Abuse and Mental Health Services Administration, 2006).  Surveyed women report that the responsibility for care of dependent children is one of the biggest barriers to treatment (Wilsnack, 1991).  This barrier can be influenced by numerous factors, including an inability to afford both childcare and substance use treatment, fear of legal consequences, and a lack of transportation (Substance Abuse and Mental Health Services Administration, 2006).  Women also face more stigma as substance abusers than men, particularly if they are pregnant or have children; they are also more likely to have suffered trauma and violence than their male counterparts (Center for Substance Abuse Treatment, 2009).  Women may also be concerned that the act of seeking treatment will cause their children to be removed from their care, causing them to hide their addiction, rather than seek treatment (Substance Abuse and Mental Health Administration, 2006).  Additionally, there are few evidence-based treatment models for women, as most models were developed by studying men (Center for Substance Abuse Treatment, 2009).  Women are also more likely to encounter social and cultural restrictions towards receiving substance abuse treatment, particularly if in an environment where men and women do not mix socially (Wilsnack, 1991).  Women who are substance abusers are more likely to live with a family member or partner who abuses substances, making treatment difficult if the partner does not support her sobriety, or does not also want to undergo treatment (Center for Substance Abuse Treatment, 2009).  Finally, women are also more likely to suffer from comorbid psychiatric diseases than men, which can complicate treatment (Lo et al., 2013).  
Among sexual minorities, disparities occur in both the prevalence of substance use disorders and treatment access, according to a national survey of 34,653 individuals over the age of 20 (McCabe et al., 2013).  Women identifying as homosexual (n=145) or bisexual (n=161) were three times more likely to have a substance use or alcohol use disorder during their lifetime compared to heterosexual women (n=19,489).  The age of drinking onset for non-heterosexual women (16.7 year, SE = 0.3) was also significantly earlier than heterosexual women (18.2 years, SE=0.1), which may provide some evidence on why the lifetime prevalence rates for alcohol use disorder are so discordant.  More alarming though, is despite the significant prevalence of substance use disorders in sexual minority women, they have similarly low rates of treatment compared to heterosexual women (McCabe et al., 2013).  So despite experiencing substance use disorders more frequently, they are not any more likely to seek treatment.  Homosexual men (n=190) were twice as likely to have a drug use disorder compared to heterosexual men (14,109), with lifetime prevalence rates of 32.7% and 15.7%, respectively, and were 1.3 times more likely to have alcohol use disorder, with a lifetime prevalence of 58.7% compared to heterosexual men, who have a lifetime prevalence rate of 47.7% (McCabe et al., 2013).  Sexual minorities also experience higher rates of psychiatric illnesses, which may contribute to their high rates of substance use disorders as they try to self-medicate or use alcohol as a coping mechanism (Bostwick et al., 2010; Hughes, Szalacha & McNair, 2010; Wilsnack et al., 2008).  A national epidemiologic survey (n=34,653) found that 56.3% of lesbian, gay, and bisexual individuals self-reported psychiatric disorders within the past 12 months, while 34.6% of heterosexuals reported psychiatric disorders (Hatzenbuehler, Keyes & Hasin, 2009).  Finally, sexual minorities with substance use disorders face unique barriers to treatment, such as stigmatizing attitudes held by providers of care, and providers who lack knowledge on their particular health needs, as well as experience stigmatizing attitudes from the other patients in a group-treatment program, decreasing the likelihood that they will complete treatment (Center for Substance Abuse Treatment, 2009).

3.0 	FACTORS AFFECTING DRUG USE
While there are environmental factors and genetic factors that can affect the likelihood an individual will develop a substance use disorder, these factors also have the ability to interact with one another, either raising or lowering a person’s risk.  While these factors exist and can be calculated to a certain degree, an individual must first initiate use of the substance; for without first using the substance, there can be no substance use disorder. 
3.1	ENVIRONMENTAL FACTORS
Initial use of a substance is required for dependence to occur, which is primarily governed by environmental factors such as peer pressure, cultural and individual views of substance use, and accessibility of the substance (Wang et al., 2012).  Recently, the college environment has seen increases in use and abuse of prescription drugs, particularly psychotherapeutic medications (Lo et al., 2013).  In 2002, 4.1% of individuals aged 18-25 reported prescription drug abuse; by 2007, this rate had risen to 4.6% (Substance Abuse and Mental Health Services Administration, 2009).  Many psychiatric conditions manifest in early adulthood, causing individuals of college-age to seek medical treatment.  Rather than dealing with the potential negative stigma associated with mental illness or inform their parents, young adults may decide to obtain psychotherapeutic drugs illegally.  Lo and colleague’s (2013) study found young adults experienced increased likelihoods of alcohol and prescription drug abuse (67% increase), alcohol abuse only (49% increase), and prescription drug abuse only (22% increase) when they experienced mental illness compared to those who did not.  Additionally, overconsumption of alcohol may be viewed as a rite of passage for many college students, as they are able to make decisions without the interference of their parents.  While the above environmental factors affect young adults more predominantly than adults over the age of 25, other environmental factors affect all age groups.  An individual’s environment can determine the types of substances available to the potential user based on awareness of the illicit drug market, and which of these substances appears appealing.  By looking at reason for referral to substance abuse treatment facilities, variations in use can be observed between rural and urban settings.  The Treatment Episode Data Set showed that rural admissions were more likely to report alcohol abuse and/or non-heroin opiate use (49.5% and 10.6%) compared to urban admissions (36.1% and 4.0%), while urban admissions were more likely to report heroin abuse and/or cocaine abuse (21.8% and 11.9%) compared to rural admissions (3.1% and 5.6%) (Center for Behavioral Health Statistics and Quality, 2012).  Opinions on the risk of developing dependence can influence an individual’s decision to initiate drug use.  Lo and colleague’s (2013) study found that the average respondent did perceive a moderate risk with consuming five or more drinks one to two times in the past two weeks, but behavior did not appear to be curbed by this knowledge.  After initiation of substance use, the transitions from recreational use to regular use and drug dependence are influenced predominantly by biological factors.  
3.2	GENETIC FACTORS
Twin studies, adoption studies, and family studies have demonstrated that drug dependence has genetic factors (Agrawal et al., 2012).  Twin studies comparing prevalence rates between monozygotic and dizygotic twins are often used to determine if a specific trait (such as substance use) is heritable.  Heritability is a statistic used to determine how much of a phenotype (trait) is due to genetic, or inherited variation among individuals in the population, where 0% indicates no genetic influence, and 100% indicates the trait is solely determined by genetics.  Monozygotic twins are genetically identical, whereas dizygotic twins share, on average, half of their genes.  For a specific trait, a higher prevalence in monozygotic twins versus dizygotic twins indicates the trait is heritable.  Family studies can also be used to determine if traits cluster within certain families and are useful in identifying genetic regions of interest for possible disease-causing genes.  Adoption studies can be used to assess if genetic or environmental factors influence disease risk, by comparing genetically similar children who have been raised in different locations, environments, etc.  
Table 1. Heritability Estimates of Various Substances of Abuse








Based on monozygotic twin studies in multiple ethnic groups, estimates on the heritability of substance use disorder have been made (Table 1).  Note that “ND” indicates estimates are “not determined.”  Heritable influences account for 40-70% of the variation in alcohol dependence (Wang, Kapoor & Goate, 2012; Agrawal & Lynskey, 2008).  For cannabis use, Wang and colleagues (2012) determined that 40-48% of the variation in cannabis initiation is influenced by heritable factors, while Agrawal and colleagues (2012) found that 51-59% of cannabis abuse is influenced by heritable factors, indicating that not only can persistence of drug use be affected by genes, but also the initial inclination to try a substance of abuse.  Heritability estimates for cocaine abuse range from 42-79%, while stimulant abuse in general is estimated to be around 33% (Tsuang et al., 1996).  Tsuang and colleagues (1996) also found that 27% of the variation in sedative abuse is influenced by genetic factors.  Like cannabis use, smoking nicotine appears to have genetic factors affecting both the initiation of use and eventual dependence-50% and 59%, respectively (Wang, Kapoor & Goate, 2012).  
Similar to other chronic diseases, multiple genes have been implicated in having an influence on substance use disorders.  There is no “addiction gene;” it is hypothesized that most of the implicated genes have a small effect individually, but create a combined risk profile for each person based on their unique genetic variation (Demers, Bogdan & Agrawal, 2014).  Single nucleotide polymorphisms (SNPs) are variations at specific locations in a DNA sequence among individuals.  These polymorphisms are naturally occurring, and can be located in either the coding region (genes) or the non-coding region of DNA.  When polymorphisms occur in or near genes, the gene product may be altered in expression level or function.  Some polymorphisms located in specific genes have been identified that produce strong effects on the development of substance use disorders (Table 2).  For the data presented in Table 2, the location of the SNP is provided, with the base-pair change indicated; for example, the majority of the population at position rs671have an adenosine (A) base, giving this the designation of major allele.  However, a minority of the population have a guanine (G) at the same position, giving this the designation of minor allele.  Major and minor allele frequency can vary across different subpopulations.  Finally, the observed effect of the minor allele is indicated in Table 2, based on association studies in human populations.  Variants in ALDH2, ADH1B and ADH1C are known to affect alcohol metabolism based on human and mouse studies, with several of these variants providing a protective influence from alcohol abuse (Agrawal et al., 2012).  The rs671A variant produces a glutamic acid amino acid at position 504, while the rs671G variant produces a lysine amino acid (Wang, Kapoor & Goate, 2012).  This Glu504Lys variation in ALDH2-present in up to 30% of East Asian populations (Osier et al., 2002), and 6% of the global population (Xu et al., 2014)-produces a nearly inactive protein product that is unable to metabolize acetaldehyde, providing a protective effect against alcohol dependence for carriers and particularly for homozygous individuals with the lysine variation (Wang, Kapoor & Goate, 2012). ADH1B has several different polymorphisms, conveying protective effects to the carriers from alcohol dependence. The ADH1B Arg48His variation found in up to 50% of individuals of Asian descent (Osier et al., 2002) produces a dehydrogenase isoenzyme that is capable of converting ethanol to acetaldehyde 70-80 times faster than the enzyme coded by the major allele Arg48 (Edenberg, 2007). The Arg370Cys variation found in individuals of African descent and certain Native American populations produces a more active enzyme, causing individuals with either the 48His or 370Cys variations to experience the negative physiological consequences of higher levels of acetaldehyde in the blood and tissue, such as nausea/vomiting, skin flushing, and dizziness (Osier et al., 1999). Individuals with a more active acetaldehyde-producing enzyme may be less likely to develop alcohol abuse due to the substantial negative physical symptoms they experience upon moderate/heavy alcohol consumption. While individuals with the ALDH2 504Lys, ADH1B 48His and 370Cys are less likely to develop alcohol use disorders, they are unfortunately at greater risk for developing esophageal squamous cell carcinoma should they abuse alcohol (Wang, Kapoor & Goate, 2012). Since metabolism of acetaldehyde-a known carcinogen-is slowed or inhibited, the chemical interacts more with the upper digestive tract in these individuals, providing a greater opportunity for cellular damage to occur and cancer to develop with alcohol use (Tanaka et al., 2010).













The DRD2/ANKK1 SNP, Taq1A rs1800497, has been associated with comorbid alcohol and drug dependence among European Americans and African Americans (Yang et al., 2008).  Common variants in the genes encoding the nicotinic acetylcholine receptor, CHRNA5/CHRNA3/CHRNB4 and CHRNB3-CHRNA6 have been identified as affecting the risk for nicotine abuse in African Americans and European Americans (Culverhouse et al., 2014).  The minor allele for rs13273442 in CHRNB3-CHNRA6 has a protective effect in both African American and European American populations, with an odds ratio of 0.77 (95% CI 0.67-0.88), while the rs6474412 minor allele variant has been identified as a risk factor in European Americans (Culverhouse et al., 2014; Thorgeirsson et al., 2010).  Variants in genes have been associated with cannabis use, but the results are inconsistent; these genes include the fatty acid amide hydrolase gene (FAAH), cannabinoid receptor 1 (CNR1), and gamma-amino-butyric acid receptor alpha subunit 2 (GABRA2) (Agrawal & Lynskey, 2009).  Variations in GABRA2 have also been implicated in alcohol use disorder among Germans (odds ratio 1.97, 95% CI 1.3-2.96) (Fehr et al., 2006), and polysubstance abuse in mouse models (Low et al., 2000).  In addition to the DRD2/ANKK1 association with cocaine abuse, variants in NCAM1, TTC12, CALCYON (Luo et al., 2004), dopamine beta hydroxylase (DBH) (Kalayasiri et al., 2007)), catechol-O-methyltransferase (COMT) (Ittiwut et al., 2011)), opioidergic genes (Zhang et al., 2009; Zuo et al., 2009)), and genes associated with circadian rhythms (Malison, Kranzler & Yang, 2006) have been associated with cocaine abuse.  Interestingly, the CHRNA5/A3/B4 SNP rs16969968, which increases the risk for nicotine dependence, appears to have a protective effect against cocaine abuse (Grucza et al., 2008).  The mu-opioid receptor, OPRM1 has several variations which may confer an increased risk for opioid abuse (Uhl et al., 1999).   Genes related to stress response have also been identified as affecting addiction.  Two SNPs in FKBP5, rs1360780 and rs3800373, have been identified as affecting heroin dependence; for both of these, the less-frequent allele provides a protective effect against dependence in African Americans (Levran et al., 2014).  In Europeans, SNPs in the galanin gene (GAL) have been associated with drug dependence (Levran et al., 2008).  SNPs in AVPR1A in African Americans (Levran et al., 2009) and MC2R in Hispanics (Proudnikov et al., 2008) have also been identified in affecting drug dependence.  Copy number variations (CNVs) at various chromosomal locations have been associated with substance use disorders, including 6q14.1 and 5q13.2 (Lin et al., 2012).  How these CNVs affect substance use disorder is currently of unclear etiology.
Gender also plays a role in the heritability of substance use disorders. Studies have found cannabis initiation is more heritable in men (48%), compared to women (40%), but the heritability of cannabis abuse is lower in men versus women (51% and 59%, respectively) (Wang, Kapoor & Goate, 2012).  Male siblings of an alcoholic have higher rates of alcoholism (50%) compared to female siblings (24%) (Demers, Bogdan & Agrawal, 2014).  Variations in GABRA2 have been associated with alcohol abuse in men, but not in women (Perry et al., 2013).
3.3	gENE-ENVIRONMENT INTERACTION
The interaction between an individual’s genes and the environment is of critical importance: a person cannot become addicted to a substance despite their genetic architecture unless they experience the substance.  Studies have shown that social environments with heavy peer drinking can negate protective genetic effects of alcohol metabolizing variants, particularly among adolescents relating to first intoxication and first DSM-V symptom (Olfson et al., 2014).  In Japan and Korea, social pressure to drink alcohol has risen so much that even individuals with the protective variants for ALDH2 and ADH1B continue to drink despite the adverse physical consequences they experience (Agrawal et al., 2012).  Stress is a unique risk factor for substance use disorder, as it has separate environmental and genetic factors of influence (Levran et al., 2014).  Individuals experience stress in their environment, and often learn how to handle stress through learned or observed behavior.  Coping skills are a learned behavior that individuals use to handle response to various stimuli, including stress.  Genetically, there are many stress-related genes whose variations can affect an individual’s response to stress, releasing glucocorticoids and activating various regions of the brain.   If an individual has a genetic variant that decreases the release of glucocorticoids, he or she may be less reactive to stressful situations.  Coping skills as an environmentally learned behavior have the ability to alter the brain’s biochemistry as well.  Individuals who use meditation, breathing exercises, or use physical exertion to cope with stressful situations change the chemical environment of their brain through these actions.  Frequent environmental exposure can also cause epigenetic changes, such as histone modification and methylation/ubiquitin pattern alterations, as particular gene coding regions are used more frequently.  These studies indicate that although genetic and environmental factors influence substance use disorder, it is the interaction of all of these factors upon an individual that is the critical component.


4.0 	substance abuse treatment
Because substance use disorders are a chronic illness, they require continual treatment.  Individuals may seek treatment through: 12 step meetings, consulting a physician, psychiatrist, psychologist or social worker, attending drug or alcohol rehabilitation, attending an outpatient clinic,  going to a detox center, crisis center, emergency room or inpatient psychiatric unit, using an employee assistance program when available, contacting a social service agency, or consulting a religious leader (McCabe et al., 2013).  While all of these types of treatment exist, access to care can vary.  Access can be affected by insurance status, geographic location, socioeconomic status, and family support.  Over the past 35 years, substance abuse treatment has seen a decrease in inpatient care, and an increase in outpatient care (Mignon, 2015), in part from the high cost and changes to insurance policies.  As the focus for substance use disorders has changed from acute care to maintenance programs and long-term recovery efforts, many individuals use multiple types of treatment during the course of their lives, and even use some concurrently.  Community-based programs like Alcoholics Anonymous and Narcotics Anonymous are located throughout the US, although some individuals may not find the format or religious undertones of these two programs appropriate for their recovery.
Substance abuse treatment not only improves public health, but also is more cost-effective than incarceration or doing nothing.  The United Nations Office on Drugs and Crime estimated that the saving to investment ratio is 3:1, where for every dollar spent on treatment, three are saved directly (United Nations Office on Drugs and Crime, 2015).  When factoring in indirect costs, the saving to investment rises to 13:1, in which every dollar invested in treatment saves thirteen.  In the US, the average cost of methadone maintenance for an individual is $4,700 per year; the cost to imprison that same substance user is $18,400 per year.  Treatment for substance-abusing criminal offenders leaves them better able to function in the community, able to cope without substance use, and can encourage the individual to become a productive member of society (Office of Probation and Pretrial Services, 2003).  In 1979, the Substance Abuse Treatment Program (SATP) was developed to help guide probation and pretrial services officers in identifying substance abusers so that they could receive treatment.  The program’s goal is to use supervision, drug testing, and treatment to promote drug abstinence.  In addition to identifying substance abusers, SATP also works to identify individuals who also suffer from other psychiatric illnesses, which often require different treatment plans to address both disorders.
Drug courts were first established in Miami in 1989, in order to bridge the gap between substance use treatment and incarceration (Chandler, Fletcher & Volkow, 2009).  Today, there are more than 2000 drug courts in the US, which help provide treatment alternatives for first-time drug offenders, juveniles, and others deemed nonviolent.  Diverting these individuals early in their substance use increases the likelihood that they will abstain from substance use following treatment, decreases societal costs for incarceration, and improves the individuals’ productivity and health outcomes.  More than 44,000 individuals are under the supervision of these probation and pretrial services officers in the US for substance abuse treatment (Office of Probation and Pretrial Services, 2003).  
Substance abuse treatment often focuses on the concept of drug-related “person, place, thing.”  This protocol works by reminding individuals that they should avoid specific external stimuli that they view as triggers, as these stimuli can induce a psychological response causing the individual to experience craving or a feeling of chemical withdrawal (McLellan et al., 2000).  These feelings can make an individual in recovery feel out of control, and potentially drive them to relapse.  Not only is this response to drug-related persons/places/things psychological, but neurochemical.  Even after prolonged abstinence, brain imaging studies have shown that former cocaine addicts’ brains react differently to images of drug use compared to non-users.  The results from these studies showed that the when the former addicts experienced cravings, the brain patterning was similar to that of the effect of the drug itself.  While these types of neurochemical changes cannot be controlled, substance users can learn to cope with the feelings brought up by such person/place/thing encounters.
4.1	medication
Medications are frequently used to aid substance abusers in their treatment.  For opioid dependence, medications can take the form of agonists, partial agonists, and antagonists, which all act upon the opioid, or μ-receptors (McLellan et al., 2000).  Methadone hydrochloride is an opioid agonist that is often prescribed for short-term use during detoxification, but can also be used as maintenance medication for individuals who have had relapses in the past (Ries et al., 2014).  While individuals on methadone may become addicted to methadone, the National Institutes of Health Consensus Conference “found it effective in reducing opiate use, crime, and the spread of infectious diseases” (McLellan et al., 2000).  Buprenorphine hydrochloride, also known as subutex or suboxone, is a partial opioid agonist also prescribed for relieving withdrawal symptoms, cravings, and maintaining abstinence in former users (Ries et al., 2014).  Alternatively, opioid antagonists like naloxone (Narcan) and naltrexone (prescribed as vivitrol), work by competitively binding the μ-receptors, blocking the effects of heroin for up to 72 hours; in the case of Narcan’s nasal spray version, EMTs, caregivers and police officers are increasingly keeping this drug on hand since its approval in November 2015, to treat acute opioid overdose (FDA News Release, 2015).  Naltrexone is also used as a maintenance medication, to provide support for individuals at risk for relapse; it can also be prescribed for alcohol use disorders, because it also prevents the euphoria experienced by alcohol users (Ries et al., 2014).  Acamprosate, another alcohol use disorder medication, can be prescribed to reduce the long-term withdrawal symptoms some individuals experience, and prevent cravings (Olive et al., 2012).  
Some of the medications used to treat substance use disorders are based on genetic discoveries.  Disulfiram, known as Antabuse, was based on knowledge of the effects of the alcohol dehydrogenase protein mutations observed most frequently in the Asian population Demers, Bogdan & Agrawal, 2014).  Disulfiram interferes with alcohol metabolism by preventing the metabolism of acetylaldehyde, thus causing nausea, flushing, vomiting, and severe discomfort, if the individual ingests alcohol (Ries et al., 2014).  Baclofen, used for the treatment of alcohol use disorders, is an agonist to GABA-B receptors, one of the genes identified as conveying a risk to substance use disorders (Agrawal et al., 2012).  Just as genetics has been involved in the creation of medications, genetics can also affect the response to medication.  Several studies have shown that carriers of the A118G variation in OPRM1 respond better to naltrexone treatment for alcohol use disorder than individuals without the 118G polymorphism (Chamorro et al., 2012; Demers, Bogdan & Agrawal, 2014). Carriers of CHRNB2 variants have experienced greater side effects (intense nausea and dizziness) to varenicline (Swan et al., 2012).  Individuals with particular variants in the promotor region for the serotonin transporter SLC6A4 have been found to respond more effectively to ondansetron for alcohol use disorder (Johnson et al., 2011).  For a more direct treatment comparison, individuals with the CC variant, rs678849, in the delta opioid receptor (OPRD1) were more responsive to methadone treatment than buprenorphine, with fewer positive urine tests 24 weeks post-treatment (Crist et al., 2013).  While all of these medications have proven effective in treating substance abuse, medication alone does not solve the problem of this chronic disease.
4.2	group therapy
Community-based substance abuse treatment is generally regarded as the most effective means of recovery and relapse prevention (Chandler, Fletcher & Volkow, 2009).  Community-based substance abuse treatment has been found to be roughly 1.8 times more effective than other methods of treatment.  Also known as group therapy, this method utilizes the therapeutic ideas of affiliation, support, and peer confrontation to allow attendees to bond in a “culture of recovery” (Center for Substance Abuse Treatment, 2005).  Group therapy can include: psychoeducational groups, skills development groups, cognitive-behavioral groups, support groups, and interpersonal process groups.  The focus of these treatment approaches is to educate individuals on substance abuse, teach skills to attain and sustain abstinence, alter thoughts and actions that contribute to substance abuse, provide a safe environment to share information, and analyze developmental issues that contribute to substance abuse and interfere with recovery.  When combined with medication such as methadone maintenance for heroin users, these methods show even greater efficacy in preventing relapse and promoting a healthier lifestyle (Chandler, Fletcher & Volkow, 2009).  In prisons where group therapy treatment is available, individuals who participate in both group therapy and counseling for substance abuse are 1.5 times less likely to reoffend (Chandler, Fletcher & Volkow, 2009).  Even more encouraging, individuals who participate in both prison-based treatment as well as community-based treatment upon release are 7 times more likely to be substance free, and 3 times less likely to be arrested.
5.0 	Mon Yough Community Services
I spent the summer of 2015 interning at Mon Yough Community Services, which offers drug and alcohol services at their facility located in McKeesport, Pennsylvania, including, recovery support services, and substance abuse treatment.  I shadowed licensed drug and alcohol counselors as they saw patients individually and led the various group programs MYCS offers.   All clients participated voluntarily; while some clients were self-referrals, others were involved in the Criminal Justice System, Department of Probation and Parole or the Department of Correction.  All potential new clients were first evaluated for intoxication, withdrawal, medical status, behavioral and emotional concerns, treatment resistance/acceptance, relapse potential, and community supports using the Pennsylvania Criteria for Patient Care (PCPC).  Diagnoses were formulated using the DSM-V and the clinical assessment, and the PCPC results were used to determine what level of care the individual required.  
MYCS operates with a tiered services program; the first tier is the Inpatient Partial Program (IPP) in which clients attend group sessions from 9am til 4pm five days a week, as well as several individual therapy sessions.  Clients in IPP attend for on average four weeks.  The second tier is the Intensive Outpatient Program (IOP), which runs groups sessions three days a week for 10 weeks, with each session running between 2 and 3 hours, plus individual therapy sessions to address specific problems or concerns.  The third tier is the Outpatient Program (OP), which has one group session each week, running for on average 10 weeks.  The facility has a licensed psychiatrist on site to oversee the client’s mental health, prescribing and altering medications as needed to assist in recovery, as well as treat comorbid psychiatric conditions.  Based on individual circumstances, the programs can be expanded or abbreviated to best assist each client.  The MYCS group sessions, at all levels of care, utilize the different types of group therapy, including cognitive-behavioral therapy and skills-based therapy, to enable clients to better understand their addiction and their triggers, and to help the clients develop positive coping skills to prevent future drug use.  
 During my time at MYCS, I saw individuals from different socioeconomic status, race, gender, and age struggle with addiction.  Some individuals had the support of their family, while others were dealing with situations of abuse, had no support network, or were with partners who were active substance abusers.  Some individuals were on medication to assist in their recovery and others comorbid psychiatric conditions.  My experience showed me that substance abuse can happen to anyone at any stage in their life, causing significant problems in the life of the individual and their loved ones.  Some clients were involved with Child Protective Services, while others had probation officers and wore ankle monitors.  Many clients had been through some form of treatment in the past, an indication of how difficult it can be to maintain abstinence.  All had suffered significant negative consequences from their substance abuse, be it the loss of their family, career, driver’s license, health or freedom.  
I had the opportunity to talk to more than 40 clients in the different group programs about environment, family history and genetics, and how these can affect substance abuse.  About 80% of individuals were surprised to learn how much genetics impacts the development of substance abuse, but upon introspection they identified family members or idols who were substance abusers.  I also asked if they thought knowing their genetic risks would have affected their decisions in the past, or would affect their decisions in the future.  Although some individuals did not feel knowledge would have affected their past decisions, 20% felt it might have prevented them from initiating substance use.  More positively, more than 50% felt that knowing their genetic risk would be helpful for future decisions, as well as helpful to their children.  Based on the discussions I had with clients, the potential for genetics to positively impact substance abuse treatment is worth investigating.
6.0 	using genetics to improve public health
Knowledge of each individual’s genetic composition has the potential to improve treatment outcomes for substance use disorders.  As described above, variants in several genes have been identified that are associated with the likelihood of an individual initiating substance use as well as the likelihood that they will become dependent.  Additionally, some genetic variants are known to affect the biochemistry of the protein product, altering an individual’s response to medication.  A negative response to treatment medication for any illness (through side effects or health complications) causes distrust with physicians and increases the likelihood that the individual will discontinue treatment.  For a subpopulation such as substance abusers, the comorbid diseases and the neurological changes they experience from substance abuse greatly limit the opportunity for medical intervention during treatment.  If a substance abuser experiences significant side effects from treatment medication, they may choose to discontinue treatment, increasing their risk for further morbidity and earlier mortality.  Implementation of a genetic screening panel may benefit the individual and improve treatment outcomes.
In the next few paragraphs, I briefly outline a possible intervention.  First, upon physician referral, individuals with a diagnosis of substance use disorder would provide a blood sample or buccal swab to test for various SNPs and CNVs that have been reported to affect substance abuse risk and response to medication.  Data on potential risk alleles would be gathered to help in future substance abuse research, whereas data from alleles that alter drug metabolism would be used to develop medication regimens.  For example, individuals with the A118G variation in OPRM1 would be preferentially placed on naltrexone, as they respond better to naltrexone therapy than those without the 118G polymorphism (Chamorro et al., 2012). Individuals without the a particular minor allele CHRNB2 variant would be placed on medication other than varenicline, as severe side effects have been documented among individuals with the major allele variant (Swan et al., 2012).  Individuals with particular variants in the promotor region for the serotonin transporter SLC6A4 would be preferentially placed on ondansetron for alcohol use disorder, as better treatment outcomes have been observed in other studies (Johnson et al., 2011; Demers, Bogdan & Agrawal, 2014).  Additionally, individuals with the CC variant rs678849 OPRD1 would be placed on methadone rather than buprenorphine, as they respond better to methadone (Crist et al., 2013).
This intervention would require cooperation from several stakeholders, including substance abusers, drug manufacturing companies, physicians, insurance companies and probation/parole officers.  Individuals with substance use disorder would be referred for genetic screening upon diagnosis or interaction with Drug Courts.  A laboratory testing facility would be required to handle the genetic screening, as well as the reporting of any medically-relevant variations.  After receiving the results of the screen, a physician would select an appropriate medication to assist in treatment, should medication been deemed appropriate and acceptable.  
For an initial intervention, individuals in Allegheny County referred to Drug Court or a physician for substance use disorder would be provided an informational pamphlet and the ability to participate in the genetic screening program.  Of those informed of the program, I would aim for 60% of these individuals providing a sample for genetic screening, with reportable results on 95% of these individuals, allowing for the possibility that a few specimens would not yield informative results.  Information regarding drug use history, substances used, length of use, and frequency of use would be obtained from 90% of screened individuals.  A key component of this intervention and later measurements, physicians would document the expected medication prescription based on standard care practices.  The short-term outcomes would include the number of individuals with genetic results suggesting a medication change, the types of medications actually prescribed, and the number of individuals who did not have a medication change due to genetic screening results.  Measuring the number of individuals with informative genetic screens (and their percentage within the tested population) would provide power and statistical significance to other outcome measurements.  Medium-term outcome measurements would include careful record-keeping of side effects for all individuals, to determine if there is a difference in side effects for each type of drug prescribed, and if there are any patterns in side effects related to genetic screen results.  Medium-term outcome measurements would focus on obtaining side effect information on 75% of individuals after 1 week, 1 month, and 60% of individuals at 3 months.  Long-term outcome measurements would focus on obtaining treatment updates on 50% of individuals after 1 year, to determine recidivism and compliance estimates.  These measurements in total would allow for a comparison of genetic screening data and longer-term abstinence rates; based on these results the screening campaign could be extended beyond Allegheny County.  
From an economic perspective, incorporating genetic testing in the treatment of substance use disorders may be beneficial.  The upfront cost of treating substance use disorders would increase with the use of a genetic screen, but many downstream costs would be mitigated.  First, initial medication after physician referral is more likely to be effective and elicit fewer side effects, resulting in fewer individuals undergoing relapse during early treatment, and fewer individuals discontinuing treatment.  By definition, earlier effective treatment should decrease the risk of morbidity and mortality from drug abuse, causing less burden of disease, decreased healthcare costs, while increasing productivity and healthy life years.  Additionally, earlier effective treatment may decrease the incidence of relapse, as well as the number of times an individual relapses, decreasing the final cost of substance use disorder treatment over the course of a person’s life.
Substance use disorders cause tremendous pain and suffering for the individual, the individual’s family, and the public.  Individuals with substance use disorders suffer significant morbidity and earlier mortality.  The economic cost of substance use disorders is significant, and can be observed in high healthcare costs, criminal justice system costs, and loss of productivity.  By incorporating genetic information in the initial treatment of substance use disorders, treatment outcomes, individual health and public health could improve, while costs associated with healthcare, the criminal court systems and loss of productivity could decrease.   Little change in prevalence rates for substance use disorders has occurred in the past few decades; the addition of genetics in treatment approaches may lead to significant benefits to individuals with substance use disorders, their families, and communities.  
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